Scholar Rock Holding Corporation
Scholar Rock Holding Corporation
Your view on SRRK
Overview
What the company does, where it operates, and who runs it.
About Scholar Rock Holding Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David L. Hallal
- Headquarters
- 301 Binney Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David L. Hallal
- Headquarters
- 301 Binney Street, Cambridge, MA, US
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.
The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Scholar Rock Holding Corporation, and the rating behind it. SRRK last traded at $55.41; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Scholar Rock Holding Corporation. Starting points for Scholar Rock Holding Corporation: EPS -$3.13, beta 0.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Scholar Rock Holding Corporation. Scholar Rock Holding Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Scholar Rock Holding Corporation. Trailing twelve-month EPS for Scholar Rock Holding Corporation stands at -$3.13. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Scholar Rock Holding Corporation. Scholar Rock Holding Corporation has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Scholar Rock Holding Corporation valued side by side against its closest peers. Scholar Rock Holding Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Scholar Rock Holding Corporation, and how their positions are changing. At a $6.64B market value, institutional positions materially move Scholar Rock Holding Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Scholar Rock Holding Corporation executives and directors. Shares of Scholar Rock Holding Corporation have traded between $22.71 and $46.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Scholar Rock Holding Corporation. Scholar Rock Holding Corporation is a $6.64B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Scholar Rock Holding Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Scholar Rock Holding Corporation. Coverage tracks Scholar Rock Holding Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.